Cuba begins clinical trial of HIV vaccine stat : nycaribnews

HAVANA,Cuba (CMC) — A therapeutic vaccine aimed at reducing the viral load of patients with Human Immunodeficiency Virus (HIV), is currently in phase one of a clinical trial, in which its safety is studied. According to the Cuban Ministry of Public Health 31 years after the first case diagnosed in the country with HIV, transmission by blood and its derivatives and mother-to-child transmission were eliminated. Prieto Correa emphasised that the country's scientific institutions, and in particular the CIGB should keep the search for vaccine candidates against HIV among its research priorities, although prevention is still the main method of avoiding contagion. The proposal presented by Prieto Correa and a team of researchers at the first Congress BioProcess 2017, which takes place in Camaguey, shows signs of efficacy, however she noted that it does not cure the disease. After preclinical studies in laboratory animals, and tests in the small group of humans, it was shown that the immune response of the organism is enhanced thanks to the use of the vaccine, although Prieto Correa insisted on not creating false expectations.




Healthy adult volunteers were given three doses of this vaccine at 28-day intervals before being challenged with exposure to the malaria parasite. That involved another small trial, and the vaccine wasn't quite as effective as this, protecting only about two-thirds of those who received it. A recent study published in Nature shows that a new vaccine for malaria is well tolerated by humans and can provide significant immunity to malaria. The authors of this study are also planning future work that will determine how long vaccine recipients remain immune to malaria. To make this new vaccine, the parasites were first rendered harmless via radiation and then rapidly frozen for preservation.


The National Institute of Allergy and Infectious Diseases (NIAID) recently began a Phase 1 clinical trial to examine an investigational vaccine that provides protection against a range of common mosquito-transmitted diseases, such as Zika virus, malaria, West Nile, and dengue fever. The clinical trial aims to enroll up to 60 healthy adults ages 18 to 50 years, all of which will be assigned one of three vaccine regimens. The vaccine, called AGS-v, was developed by a joint venture of two London-based pharmaceutical companies, SEEK and hVIVO. Unlike other vaccines which transmit a small amount of the virus into a person's bloodstream to trigger an immune response, the AGS-v vaccine targets mosquito saliva. A final clinic visit will take place approximately 10 months after the initial mosquito feeding to determine the vaccine's overall effectiveness.



collected by :Lucy William

To follow all the new news about Health care